|
SFRS6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7611023750419E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.37779999631604E-08 |
| Normal-vs-Stage2 |
3.2753999956725E-08 |
| Normal-vs-Stage3 |
5.69544411632705E-14 |
| Normal-vs-Stage4 |
5.28419996648211E-09 |
| Stage1-vs-Stage2 |
2.492000E-01 |
| Stage1-vs-Stage3 |
1.984100E-03 |
| Stage1-vs-Stage4 |
2.582300E-02 |
| Stage2-vs-Stage3 |
2.728600E-01 |
| Stage2-vs-Stage4 |
4.053600E-01 |
| Stage3-vs-Stage4 |
9.948200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.40990552566223E-11 |
| Normal-vs-AfricanAmerican |
4.044700E-04 |
| Normal-vs-Asian |
9.57480000000066E-05 |
| Caucasian-vs-AfricanAmerican |
5.454200E-01 |
| Caucasian-vs-Asian |
1.057360E-01 |
| AfricanAmerican-vs-Asian |
6.291600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.04320030181304E-10 |
| Normal-vs-Female |
7.7941986198482E-11 |
| Male-vs-Female |
7.061200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.051300002608E-08 |
| Normal-vs-Age(41-60Yrs) |
2.35299557616031E-11 |
| Normal-vs-Age(61-80Yrs) |
3.30290017558355E-10 |
| Normal-vs-Age(81-100Yrs) |
4.163900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.834000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.767920E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.594810E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.699000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.694200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.109600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.36919999957652E-07 |
| Classical-VS-Follicular |
1.503220E-01 |
| Classical-VS-Other |
7.412800E-01 |
| Classical-VS-Normal |
2.40069997214931E-09 |
| Tall-VS-Follicular |
5.702700E-03 |
| Tall-VS-Other |
2.221000E-01 |
| Tall-VS-Normal |
1.36557432028894E-14 |
| Follicular-VS-Other |
8.453400E-01 |
| Follicular-VS-Normal |
2.45850000357706E-08 |
| Other-VS-Normal |
1.099670E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.84929857485849E-11 |
| Normal-vs-N1 |
3.52249999999721E-05 |
| N0-vs-N1 |
3.911600E-01 |
|
|
